TA800015 C17orf37 antibody

C17orf37 (XTP4) mouse monoclonal antibody, clone OTI4D4 (formerly 4D4)

See related secondary antibodies

Search for all "C17orf37"

0.1 ml / $360.00
Delivery Time: 2-3 working days*
(*) valid for US customers only

TrueMAB

Quick Overview

Mouse anti Human C17orf37 OTI4D4

TA800015

More Views

  • TA800015
  • TA800015
  • TA800015

Product Description for C17orf37

Mouse anti Human C17orf37 OTI4D4.
Presentation: Purified
Product is tested for Flow Cytometry, Paraffin Sections, Western blot / Immunoblot.

Properties for C17orf37

Product Category Primary Antibodies
Target Category
Quantity 0.1 ml
Synonyms HBV X-transactivated gene 4 protein, Protein C35, Uncharacterized protein C17orf37, XTP4
Presentation Purified
Reactivity Hu
Applications F, P, WB
Clonality Monoclonal
Clone OTI4D4
Host Mouse
Isotype IgG2a
Shipping to Europe, USA/Canada
PDF datasheet View Datasheet
Manufacturer OriGene Technologies, Inc.

Datasheet Extract

Immunogen
Swiss Prot Num:
Q9BRT3
Immunogen:
Full length human recombinant protein of human C17orf37 (NP_115715) produced in E.coli.
GeneID:
84299
Isotype control AM03096PU-N
Application WB 1:2000
IHC 1:150
FLOW 1:100
Format
Purification:
Purified from mouse ascites fluids by affinity chromatography
Buffer System:
PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
State:
Purified

Accessory Products

Proteins and/or Positive Controls

Proteins for C17orf37 (3 products)

Catalog No. Species Pres. Purity   Source  

C17orf37

C17orf37 Human > 80 %
Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps.
Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining.
HEK293 cells
20 µg / $748.00
  OriGene Technologies, Inc.

C17orf37 (1-112, His-tag)

C17orf37 Human Purified > 95 % by SDS - PAGE E. coli
0.5 mg / $820.00
  OriGene Technologies GmbH

C17orf37 (1-112, His-tag)

C17orf37 Human Purified > 95 % by SDS - PAGE E. coli
0.1 mg / $320.00
  OriGene Technologies GmbH
  • LinkedIn